NADAC acquisition cost data for AMANTADINE 50 MG/5 ML SOLUTION. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00121064616 | $0.0191 | 2022-12-21 | Rx |
| 50383080716 | $0.0191 | 2022-12-21 | Rx |
| 60432009316 | $0.0191 | 2022-12-21 | Rx |
| 00121064616 | $0.0191 | 2022-12-21 | Rx |
| 50383080716 | $0.0191 | 2022-12-21 | Rx |
| 60432009316 | $0.0191 | 2022-12-21 | Rx |
Generic: Amantadine HCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $37.6M | 493,408 | 96,191 | $0.9552 |
| 2020 | $35.7M | 488,195 | 92,849 | $0.8790 |
| 2021 | $34.3M | 471,399 | 92,465 | $0.8531 |
| 2022 | $32.3M | 473,797 | 92,947 | $0.8348 |
| 2023 | $31.5M | 500,027 | 98,048 | $0.7333 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $3.7M | 47,640 | 9,129 |
| California | $2.5M | 40,584 | 9,139 |
| Florida | $2.1M | 30,258 | 7,091 |
| Pennsylvania | $1.9M | 33,183 | 5,951 |
| Texas | $1.8M | 28,335 | 6,514 |
| Ohio | $1.3M | 21,222 | 4,182 |
| Illinois | $1.3M | 20,175 | 4,019 |
| Michigan | $1.1M | 16,215 | 3,312 |
| Massachusetts | $1.0M | 15,520 | 3,125 |
| North Carolina | $982.1K | 16,901 | 3,523 |
| Indiana | $903.2K | 15,290 | 2,901 |
| New Jersey | $745.6K | 12,333 | 2,583 |
| Georgia | $703.7K | 14,291 | 2,586 |
| Arizona | $677.0K | 9,838 | 2,298 |
| Wisconsin | $672.3K | 10,701 | 2,061 |
| Tennessee | $613.3K | 10,116 | 2,143 |
| Missouri | $609.3K | 10,914 | 2,021 |
| Washington | $563.7K | 9,066 | 1,810 |
| Virginia | $512.2K | 7,874 | 1,813 |
| Puerto Rico | $492.9K | 9,717 | 1,649 |
| Kentucky | $477.4K | 7,545 | 1,752 |
| Minnesota | $464.3K | 7,245 | 1,463 |
| Alabama | $457.9K | 7,073 | 1,439 |
| Connecticut | $447.0K | 6,747 | 1,313 |
| Maryland | $417.3K | 6,806 | 1,369 |
| Colorado | $396.6K | 6,274 | 1,452 |
| Oregon | $384.5K | 6,230 | 1,275 |
| Louisiana | $383.3K | 8,332 | 1,575 |
| South Carolina | $368.8K | 6,643 | 1,476 |
| Oklahoma | $356.3K | 5,475 | 1,207 |
| Iowa | $268.5K | 4,497 | 846 |
| Kansas | $261.0K | 4,621 | 851 |
| Nebraska | $247.0K | 4,526 | 744 |
| Arkansas | $236.8K | 4,565 | 878 |
| New Mexico | $194.8K | 2,646 | 611 |
| Utah | $191.4K | 2,865 | 617 |
| Nevada | $182.5K | 2,738 | 745 |
| West Virginia | $174.8K | 3,065 | 655 |
| New Hampshire | $167.0K | 2,636 | 553 |
| Idaho | $150.4K | 2,523 | 502 |
| Mississippi | $143.6K | 3,297 | 596 |
| Rhode Island | $129.3K | 1,945 | 386 |
| Maine | $111.7K | 1,698 | 388 |
| South Dakota | $93.9K | 1,791 | 309 |
| Delaware | $88.5K | 1,361 | 305 |
| Montana | $73.4K | 1,751 | 302 |
| District of Columbia | $65.5K | 955 | 239 |
| Vermont | $57.8K | 906 | 180 |
| North Dakota | $53.1K | 828 | 169 |
| Hawaii | $52.3K | 797 | 215 |
| Alaska | $30.4K | 556 | 111 |
| Wyoming | $24.1K | 418 | 75 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.